|Ms. Trisha M. Millican||Chief Financial Officer||381.47k||N/A||1973|
|Dr. Hubert C. Chen||Chief Medical Officer||440.14k||N/A||1969|
|Dr. Preston S. Klassen||Pres, CEO & Director||N/A||N/A||1969|
|Ms. Patricia Millican||Chief Financial Officer||N/A||N/A||1973|
|Ms. Catherine C. Lee||Sr. VP & Gen. Counsel||N/A||N/A||1974|
|Ms. Theresa Lowry||VP of HR||N/A||N/A||N/A|
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities related to fibroblast growth factor 1. Metacrine, Inc. was founded in 2014 and is headquartered in San Diego, California.
Metacrine, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.